Management of atrial fibrillation after transcatheter aortic valve replacement: Challenges and therapeutic considerations

Trends Cardiovasc Med. 2021 Aug;31(6):361-367. doi: 10.1016/j.tcm.2020.06.007. Epub 2020 Jun 27.

Abstract

Atrial Fibrillation (AF) is very common among patients with severe aortic stenosis. Moreover, new onset AF (NOAF) is a frequent finding after Transcatheter Aortic Valve Replacement (TAVR). There is a significant impact of AF on outcomes in patients undergoing TAVR including mortality, thrombo-embolic and bleeding events. There is lack of clear evidence about the optimal management of AF in TAVR patients. This review aims to summarize the epidemiology, predictors, prognosis, therapeutic considerations and challenges in the management of AF in patients undergoing TAVR.

Keywords: Anticoagulation; Atrial fibrillation; Transcatheter aortic valve replacement.

Publication types

  • Review

MeSH terms

  • Ablation Techniques* / adverse effects
  • Ablation Techniques* / mortality
  • Anti-Arrhythmia Agents / adverse effects
  • Anti-Arrhythmia Agents / therapeutic use*
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / mortality
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / therapy*
  • Cardiac Catheterization* / adverse effects
  • Cardiac Catheterization* / instrumentation
  • Cardiac Catheterization* / mortality
  • Comorbidity
  • Humans
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Prevalence
  • Risk Assessment
  • Risk Factors
  • Stroke / mortality
  • Stroke / prevention & control
  • Transcatheter Aortic Valve Replacement / adverse effects*
  • Transcatheter Aortic Valve Replacement / mortality
  • Treatment Outcome

Substances

  • Anti-Arrhythmia Agents
  • Anticoagulants
  • Platelet Aggregation Inhibitors